Signify Health Expands In-Home Diagnostic and Preventive Services

Trending News ☀️

Signify Health is expanding its in-home diagnostic and preventive services offerings for Medicare Advantage and Medicaid plan members. The newest addition is a spirometry test to detect chronic obstructive pulmonary disease . Signify plans to offer the test in select geographies beginning in 2022. The company noted that the offering supports the early detection, diagnosis, and management of some of the leading causes of mortality among Medicare members, including COPD, peripheral arterial disease, colorectal cancer, chronic kidney disease, diabetes, and low bone density.

The addition of a spirometry test to detect COPD will help to improve the early detection and management of this condition. This is especially important given that COPD is one of the leading causes of mortality among Medicare members. We hope that other companies will follow Signify Health’s lead in expanding their in-home diagnostic and preventive services offerings.

Stock Price

On Tuesday, SIGNIFY HEALTH ($NYSE:SGFY) stock opened at $29.3 and closed at $29.2, down by 0.1% from prior closing price of 29.3. The company’s expansion into in-home services is seen as a positive move, as it will allow them to reach more patients and provide them with necessary care. However, some investors are concerned that the expansion may not be profitable in the long run. Overall, the expansion is seen as a positive move by the company that will allow them to provide better care for their patients.

VI Analysis

Signify Health is a strong growth company with medium assets and profitability, and weak dividend potential. Its intermediate health score of 6/10 indicates that it is likely to be able to pay off debt and fund future operations. Signify Health is classified as a ‘cheetah’ company, which means that it has achieved high revenue or earnings growth but is considered less stable due to lower profitability. This type of company may be of interest to investors who are looking for high growth potential but are willing to accept higher risks.

VI Peers

In the healthcare industry, there is intense competition between Signify Health Inc and its competitors Accolade Inc, 1Life Healthcare Inc, and Teladoc Health Inc. All four companies are fighting for a larger share of the market, and each has its own unique strengths and weaknesses.

– Accolade Inc ($NASDAQ:ACCD)

Accolade Inc. is a provider of personalized health and benefits solutions. The company’s solutions include a mobile app and website that offer personalized guidance and support for health, benefits, and daily life; and an engagement platform that helps employers drive better health and benefits outcomes for their employees. Accolade Inc. has a market cap of $818.66M as of 2022 and a return on equity of -47.5%.

– 1Life Healthcare Inc ($NASDAQ:ONEM)

Life Healthcare Inc is a US based company that focuses on providing healthcare services. As of 2022, the company has a market cap of 3.34B and a ROE of -20.76%. The company has been struggling financially in recent years, which is reflected in its ROE. Despite this, the company continues to provide healthcare services to its patients.

– Teladoc Health Inc ($NYSE:TDOC)

Teladoc Health Inc is a company that provides telehealth services. It has a market cap of 4.11B as of 2022 and a Return on Equity of -81.03%. The company offers a variety of services such as primary care, behavioral health, and more.

Summary

Signify Health is a healthcare technology company that offers in-home diagnostic and preventive services. The company has received funding from a number of investors, including Kleiner Perkins, Google Ventures, and Khosla Ventures. Signify Health is expanding its services to include more in-home health services, such as primary care, behavioral health, and chronic care management. The company is also working on developing a mobile app that will allow patients to access their health data and schedule appointments with their care team.